Protect Your Patients, Your License, and Your Margins The FDA says BPC-157 isn't approved for patients right now
Takai, et al (2015)
Neelakantan et al., NNMT inhibition reverses diet-induced obesity in mice (2018) Babula et al., NNMT inhibition mitigates obesity-related metabolic dysfunction: fat mass, glucose tolerance, hepatic steatosis, pharmacokinetics and off-target screen (Diabetes Obes Metab, 2024) Dimet-Wiley et al., NNMT inhibition mimics and boosts exercise-mediated muscle improvements in aged mice (Sci Rep, 2024) NNMT inhibition and muscle function in aged mice (2019) Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (2022): the diet-switch combination study Awosemo et al., rat pharmacokinetics of 5-amino-1MQ (2021) NNMT in metabolism and disease: review Sigma-Aldrich: 5-Amino-1MQ iodide product data (CAS 42464-96-0) FDA: bulk drug substances used in compounding under section 503A Disclaimer: Informational and research purposes only, not medical advice
ProHealix gave me momentum to push through plateaus.
For type 2 diabetes trials, criteria were applied in sequence: age 18-75 years (19-75 for Korea), BMI 25 kg/m 2 , HbA1c 7.0-10.0%, and eGFR 30 mL/min/1.73m 2
